156

서 론

,

, 1).

50

,

50%

,

15-25%2).

,

( , , , ),

,

,

, , 3).

,

, ,

90%

2007 8 10 2007 8 12

2007 8 27

: , 503-310 543-8,

6

(Tel : 062-670-6421, Fax : 062-670-6767,

E-mail : songbk@wonkwang.ac.kr)

이승희, 신진봉, 전용철, 김상우. 송봉근

원 저

A Clinical Study of Medical Care on Chronic Prostatitis

Seung-hee Lee, Jin-bong Shin, Yong-cheol Jeon, Sang-woo Kim, Bong-keun Song

Department of Oriental Internal Medicine, Wonkwang University, College of Oriental Medicine, Kwangju, Korea

Objectives : Chronic prostatitis is a common disease among adult men, yet it is very difficult to diagnosis and treat. This study was designed to evaluate the clinical effects of herb medicine, acupuncture, and herbal acupuncture therapy

on chronic prostatitis.

Methods : We investigated 15 chronic prostatitis patients with NIH-CPSI (National Institutes of Health Chronic

Prostatitis Symptom Index). They were treated with herb medicine, acupuncture, and herbal acupuncture therapy.

Results : After the treatment, NIH-CPSI decreased significantly. As the period of treatment for prostatitis was

longer, the cure rate was higher respectively. Conclusions : These findings suggest that oriental medical treatment for chronic prostatitis may promote medical

cure.

Key Words : chronic prostatitis, herb medicine, acupuncture, herbal acupuncture, cure period, NIH-CPSI

28 3 (2007 9 )J Korean Oriental Med 2007;28(3):156-164

4 :

157

4).

,

.

, 3 , ,

,

, Litwin 5)

National Institutes of Health Chronic Prostatitis

Symptom Index(NIH-CPSI) .

6,7),

6,7),

6.7),

8,9)

, 8),

9)

9),

10),

11),

12) .

15

, , ,

,

.

연구대상 및 방법

1. 연구대상

2007 2 22 2007 9 3

6 1

, 3 , 1

.

2. 치료방법

1)

, , , ,

, , New

Herbs Scientific name Dose

(Rhizoma Rehmanniae) Rehmannia glutinosa LIBOCH. 10g

(Flos Lonicerae) Lonicera japonica THUNB. 8g

(Fructus Meliae Toosendan) Melia toosendan SIEB. et ZUCC. 8g

(Herba Lycopi) Lycopus ramosissimus var. japonicus KITAMURA 8g

(Herba Taraxaci) Taraxacum platycarpum H. 8g

(Radix et Rhizoma Reynoutriae) Reynoutria elliptica (KOIDZ.) MIQ. 8g

(Fructus Corni) Cornus officinalis SIEB. et ZUCC. 6g

(Rhizoma Dioscoreae) Dioscorea batatas DECAISNE 6g

(Bulbus Fritillariae) Fritillaria ussuriensis MAXIM. 6g

(Radix Sophorae Flavescentis) Sophora flavescens AITON. 6g

(Herba Houttuyniae) Houttuynia cordata THUNB. 6g

(Cortex Moutan Radicis) Paeonia suffruticosa ANDR. 4g

(Poria) Poria cocos WOLF. 4g

(Rhizoma Alismatis) Alisma canaliculatum ALL. BR. et BOUCHE 4g

(Herba Patriniae) Patrinia villosa JUSS. 4g

Total amount 96g

(663)

28 3 (2007 9 )

158

pointer SJ-106 DC-9V, 11.8mA,

32Hz, 3-4 3 , 1 20

. .

2)

.

6

, ,

, , , , , ,

(Table 1).

3)

26 gauge 1ml syringe(Becton

Dickinson, U.S.A.) 3 , 1

1cc .

(Rhizoma Coptidis),

(Cortex Phellodendri), (Radix Scutellariae),

NIH (NIH-CPSI)

.

1. , ?

( ) 1 0

1 0

( ) 1 0

, 1 0

2. ?

1 0

1 0

3.

?

0 1 2

3 4 5

4.

?

0 1 2 3 4 5 6 7 8 9 10

II.

5.

?

0 5 1 1 2

3 4 5

6. 2

?

0 5 1 1 2

3 4 5

III.

7.

?

0 1 2 3

8. ?

0 1 2 3

IV.

9.

?

0 1

2 3

4 5

6

: 1, 2, 3, 4 ( )

: 5, 6 ( )

: 7, 8, 9 ( )

: ( )

(664)

4 :

159

(Fructus Gardeniae)13).

3. 치료성적의 평가

NIH-CPSI

(Table 2).

2 ,

,

, ,

,

.

10

Excellent, 10-5 Good, 5

Fair,

Poor , 15

.

4. 통계방법

±

, paired t-test

95% .

결 과

1. 환자의 연령, 병력기간, 치료기간

20 1 , 30 4 , 40

3 , 50 7 ,

45.46±10.02 . 1-2 7 , 2-3

6 , 3 1 , 30 1 .

2 4 2 , 4 6

2 , 6 8 1 , 8 10

3 . 10 7

66.22±33.81 (Table 3).

2. 증상 분석

12 , 9 ,

9 , 5 , 11 ,

8 , 9 . 11 (Table 4).

3. 치료 성적

1) NIH-CPSI

10.86±3.22 5.4±3.01,

Mean of Age (Years) Mean of Treatment Duration (days)

45.46±10.02a) 66.22±33.81

a): Mean standard deviation

Symptoms

frequency 12a) reduced urine force 8

abdominal pain 9 Tenesmus 10

perineal pain 9 Sexual dysfunction 5

Nocturia 11 voiding pain 9

a): No. of Patients

(665)

28 3 (2007 9 )

160

6.26±2.31 3.06±1.86,

5.06±1.22

3±1.69, 5±0.75

2.93±1.43, 27.2±3.94 14.6± 5.27

(Fig. 1, Table 5).

2) NIH-CPSI

15

Excellent 9

, Good 4 , Fair 2 , Poor 0 .

3)

4 , 4-8

, 8

. 4 21.56%, 4-8

31.30%, 8-12 57.48%, 12

60.51% .

8 8

(Table 6).

고 찰

25%14), 50

, ,

, 15,16)

.

,

Category Pre-treatment Post-treatment

Pain 10.86±3.22a)

5.4±3.01

Urinary symptoms 6.26±2.31 3.06±1.86*

Impact of symptoms 5.06±1.22 3±1.69

Quality of life 5±0.75 2.93±1.43

Total 27.2±3.94 14.6± 5.27

a): Mean standard deviation, *: P 0.05

35

30

25

20

15

10

5

0

NIH

-C

PSI

Pain Urinarysymptoms

Impact ofsymptoms

Quality oflife

Total

Pre-treatment

Post-treatment

****

(666)

4 :

161

,

90% 14,15)

.

, ,

pH

, 14,15)

.

,

,

, ,

.

.

,

17). 1999 Litwin

4)

,

,

9

NIH (NIH-CPSI)

,

,

17,18).

,

.

,

, , ,

.

,

, , ,

19).

, ,

20).

,

, 21).

, , 22).

, , , 22).

,

, 22).

,

,

.

(667)

28 3 (2007 9 )

162

. 6

, , , ,

, , , , ,

.

,

, , , ,

, ,

. 23)

,

, ,

, , , , ,

, , , ,

, 24)

, ,

,

, , ,

.

,

, ,

, ,

.

fosfomycin 25)

. Amikacin Sulfate 26) ,

. , ,

, ,

,

,

.

, ,

NIH

(NIH-CPSI)

, 2

. 15 ,

20 50 ,

45.46±10.02 , 66.22

±33.81 (Table 3).

,

, , ,

, 12 , 11 ,

, 9 , 8

, 5 (Table 4).

NIH-CPSI

, , ,

,

(Fig. 1,

Table 5).

4

31.56%, 4-8 31.30%, 8

-12 57.48%, 12

Period of cure Cure rate

<4 week 21.56%

4-8 week 31.30%

8-12 week 57.48%

>12 week 60.51%

(668)

4 :

163

60.51% ,

.

(Table 6).

, , , ,

, , ,

,

,

. 12)

NIH-CPSI

,

.

, ,

,

.

결 론

2007 2 2007 9 8

,

, ,

15

.

, NIH-CPSI

, , ,

.

.

참고문헌

1. . . . .

1999;68-73.

2. . . . ;

2003.571.

3. , .

. . 1982;

23(3):396-403.

4. The National Institutues of Health chronic

prostatitis symptom index: development and

validation of a new outcome measure. Chronic

Prosatitis Collaborative Research Network. J

Urol. 1999;162(2)369-375.

5. Litwin MS, Collins MM, Fowler FJ Jr, Nickel

JC, Calhoun EA, Pontari MA, et al. The

national institutes of health chronic prostatitis

sympton index: development and validation of

a new outcome measure. J Urol. 1999;162:

369-75.

6. , , , .

1991;679-688.

7. , , , .

. .

1994;15:211-30.

8. ,

, , . 1994;15(1):212.230.

9. .

. .

. 1995;3:(2):307-313.

10. , . 40

. .

. 2000;8(2):245-257.

11. , , , , .

.

. 2000;21(4):615-9.

12. , , , , ,

.

(669)

28 3 (2007 9 )

164

. . 2004;25(4):

1-8.

13. . . .:

. 1999;13-4, 128-33, 163-5.

14. . . .

. 2001;156-61.

15. , , , , ,

. . . . 2001;51-78.

16. , , .

.

. 1998;39(8):751-5.

17. , , . NIH-

. . 2001;42(5)

:511-2.

18. , , . 19

. . 2001;42(1)

:85-92.

19. . . .

. 2003;22(3):180-181.

20. . .

. 1999;26(4):4-5.

21. . .

. . 2001;21(5):5-6.

22. . . .

. 2002;21(12):745-756.

23. , . 32 .

. 1996;11:40.

24. . 137

. . 1998;5:294.

25. , , .

minocycline fosfomycin

. .

1990;31(6):863-869.

26. , , , , .

Fosfomycin

. . 1995;

36(3):295-8.

27. , , , , .

.

. 2006:27(3):61-72.

(670)